CRL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRL is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who wants a clear immediate entry. The stock has some supportive long-term signals, but the current technical setup is still weak and the latest earnings trend is only modestly improving. My direct view: hold and wait for a cleaner trend reversal rather than buying immediately.
The chart setup is still bearish. MACD histogram is negative and expanding, RSI at 38.13 shows weak but not oversold momentum, and the moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5. Price at 165.56 is sitting just above S1 support at 164.718, which means it is close to a key floor but not yet showing strong reversal confirmation. The recent pattern analysis suggests only a modest short-term upside bias, but not enough to call this a solid long-term buy right now.
Barclays raised its price target to $210 and keeps Overweight. RBC initiated coverage with an Outperform rating and a $215 target, citing a potential inflection in preclinical R&D spend and improving long-term growth visibility. Evercore added CRL to its Tactical Outperform list. Congress trading data is mildly positive, with 1 recent purchase and no sales, suggesting some influential buying interest. The stock also has a favorable long-term setup if the sector recovery thesis plays out.
No news in the recent week means there is no fresh event catalyst to drive momentum. Revenue in Q4 2025 declined 0.83% YoY, and net income remains negative at -276.6M even though losses improved year over year. JPMorgan cut its target to $160 and kept Neutral, while several firms reduced targets after softer guidance and mixed Q4 results. Hedge funds and insiders are both neutral, so there is no strong ownership-backed buying signal. AI Stock Picker and SwingMax both show no signal today.
Latest quarter shown is 2025/Q4. Revenue fell slightly to 994.2M, down 0.83% YoY, which indicates growth is still soft. Gross margin improved to 30.96%, a positive sign of operational improvement. Net income was still negative at -276.6M, though the loss improved 28.21% YoY, and EPS improved 33.18% YoY to -5.62. So the quarter shows better profitability trends, but not yet a true turnaround in earnings.
Analyst sentiment is mixed but leaning constructive. Recent upgrades/positive actions include Barclays raising its target to $210 with Overweight, RBC initiating at Outperform with $215, and Evercore keeping Outperform with $200. Offsetting that, JPMorgan is Neutral with a lower $160 target, and several firms cut targets after Q4 and softer guidance. Wall Street’s pro view is that CRL has a potential long-term inflection in preclinical spending and sentiment is depressed; the con view is that growth and margin expectations still need to prove out and near-term fundamentals remain uneven.
